Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels

被引:16
|
作者
Lee, Chan Joo [1 ,2 ]
Lee, Yunbeom [3 ]
Park, Sungha [1 ,2 ]
Kang, Seok-Min [1 ,2 ]
Jang, Yangsoo [1 ,2 ]
Lee, Ji Hyun [4 ]
Lee, Sang-Hak [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Div Cardiol,Dept Internal Med, Seoul, South Korea
[2] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea
[3] Kyung Hee Univ, Grad Sch, Dept Med, Seoul, South Korea
[4] Kyung Hee Univ, Coll Med, Dept Clin Pharmacol & Therapeut, Seoul, South Korea
来源
PLOS ONE | 2017年 / 12卷 / 10期
基金
新加坡国家研究基金会;
关键词
APOLIPOPROTEIN-B; GENETIC-VARIANTS; FAMILIAL HYPOBETALIPOPROTEINEMIA; MOLECULAR DIAGNOSIS; HEART-DISEASE; FATTY LIVER; LOW LDL; MUTATIONS; JAPANESE; DYSLIPIDEMIAS;
D O I
10.1371/journal.pone.0186446
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Screening of variants, related to lipid metabolism in patients with extreme cholesterol levels, is a tool used to identify targets affecting cardiovascular outcomes. The aim of this study was to examine the prevalence and characteristics of rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol (LDLC) levels. Methods Among 13,545 participants enrolled in a cardiovascular genome cohort, 22 subjects, whose LDL-C levels without lipid-lowering agents were <= 1 percentile (48 mg/dL) of Korean population, were analyzed. Two target genes, APOB and PCSK9, were sequenced by targeted next-generation sequencing. Prediction of functional effects was conducted using SIFT, PolyPhen-2, and Mutation Taster, and matched against a public database of variants. Results Eight rare variants of the two candidate genes (five in APOB and three in PCSK9) were found in nine subjects. Two subjects had more than two different rare variants of either gene (one subject in APOB and another subject in APOB/PCSK9). Conversely, 12 common variants (nine in APOB and three in PCSK9) were discovered in 21 subjects. Among all variants, six in APOB and three in PCSK9 were novel. Several variants previously reported functional, including c. C277T (p. R93C) and c. G2009A (p. G670E) of PCSK9, were found in our population. Conclusions Rare variants of APOB or PCSK9 were identified in nine of the 22 study patients with extremely low LDL-C levels, whereas most of them had common variants of the two genes.The common novelty of variants suggested polymorphism of the two genes among them. Our results provide rare genetic information associated with this lipid phenotype in East Asian people.
引用
收藏
页数:13
相关论文
共 50 条
  • [31] Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial
    Sullivan, David
    Olsson, Anders G.
    Scott, Rob
    Kim, Jae B.
    Xue, Allen
    Gebski, Val
    Wasserman, Scott M.
    Stein, Evan A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 308 (23): : 2497 - 2506
  • [32] PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment Reasons for Geographic and Racial Differences in Stroke Study (REGARDS)
    Mefford, Matthew T.
    Rosenson, Robert S.
    Cushman, Mary
    Farkouh, Michael E.
    McClure, Leslie A.
    Wadley, Virginia G.
    Irvin, Marguerite R.
    Bittner, Vera
    Safford, Monika M.
    Somaratne, Ransi
    Monda, Keri L.
    Muntner, Paul
    Levitan, Emily B.
    CIRCULATION, 2018, 137 (12) : 1260 - 1269
  • [33] PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects
    Pedro-Botet, Juan
    Badimon, Lina
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 3 - 8
  • [34] How Do PCSK9 Inhibitors Stack Up to Statins for Low-Density Lipoprotein Cholesterol Control?
    Zimmerman, Marj P.
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (08): : 436 - 442
  • [35] Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
    Sonia Nava-Salazar
    Arturo Flores-Pliego
    Giovanni Pérez-Martínez
    Sandra Parra-Hernández
    America Vanoye-Carlo
    Francisco Ibarguengoitia-Ochoa
    Otilia Perichart-Perera
    Enrique Reyes-Muñoz
    Juan Mario Solis-Paredes
    Salvador Espino y Sosa
    Guadalupe Estrada-Gutierrez
    Reproductive Sciences, 2022, 29 : 3242 - 3253
  • [36] Resistin Modulates Low-Density Lipoprotein Cholesterol Uptake in Human Placental Explants via PCSK9
    Nava-Salazar, Sonia
    Flores-Pliego, Arturo
    Perez-Martinez, Giovanni
    Parra-Hernandez, Sandra
    Vanoye-Carlo, America
    Ibarguengoitia-Ochoa, Francisco
    Perichart-Perera, Otilia
    Reyes-Munoz, Enrique
    Mario Solis-Paredes, Juan
    Espino y Sosa, Salvador
    Estrada-Gutierrez, Guadalupe
    REPRODUCTIVE SCIENCES, 2022, 29 (11) : 3242 - 3253
  • [37] Turnover Rates of the Low-Density Lipoprotein Receptor and PCSK9: Added Dimension to the Cholesterol Homeostasis Model
    Dandan, Mohamad
    Han, Julia
    Mann, Sabrina
    Kim, Rachael
    Mohammed, Hussein
    Nyangau, Edna
    Hellerstein, Marc
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2021, 41 (12) : 2866 - 2876
  • [38] THE ACHIEVEMENT OF THE LOW-DENSITY LIPOPROTEIN CHOLESTEROL TARGET IN SUBJECTS WITH FAMILIAL HYPERCHOLESTEROLEMIA: THE ROLE OF PCSK9 INHIBITORS
    Rizos, C.
    Athyros, V.
    Antza, C.
    Attilakos, A.
    Elisaf, M.
    Zacharis, E.
    Rallidis, L.
    Katsiki, N.
    Kiour, E., I
    Kolovou, G.
    Loulakakis, M.
    Boufidou, A.
    Skoumas, I.
    Florentin, M.
    Liberopoulos, E.
    ATHEROSCLEROSIS, 2018, 275 : E176 - E176
  • [39] Antihyperlipidemic therapies targeting PCSK9: Novel therapeutic agents for lowering low-density lipoprotein cholesterol
    Liu, Mi-Hua
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 195 : 212 - 214
  • [40] DISTANCE TO TARGETS OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL AND ELIGIBILITY FOR TREATMENT WITH PCSK9 INHIBITORS IN PATIENTS AT HIGH CARDIOVASCULAR RISK
    Barkas, F.
    Elisaf, M.
    Dimitriou, T.
    Liamis, G.
    Rizos, E.
    Liberopoulos, E.
    ATHEROSCLEROSIS, 2019, 287 : E185 - E186